- Patients with acute myeloid leukemia (AML) who relapse
Why this matters
- Relapse after allo-HSCT accounts for 30%-40% of posttransplant deaths.
- Analysis of outcomes in 83 patients with AML who experienced relapse after allo-HSCT.
- All patients studied had undergone transplantation between 2010 and 2016 and experienced relapse before the end of 2017.
- 80 patients had AML; 3 had chronic myelomonocytic leukemia or high-risk myelodysplastic syndromes.
- Patients were stratified by intention to treat: curative (CIT; n=50) vs best supportive care (BSC; n=33).
- Median age at time of allo-HSCT: 54 (interquartile range, 47-62) years.
- Funding: None disclosed.
- 44% in the CIT group achieved complete remission (CR) with reinduction chemotherapy; one-half of these patients survived through observation.
- 69% of survivors had received high-intensity cytarabine treatment and subsequent immunologic consolidation.
- Relapse at
- >50% experienced relapse at
- Retrospective data.